Immatics

Immatics ROE

The Return on Equity (ROE) of Immatics (IMTX) as of Nov 19, 2026 is -40.58 %. In the previous year, Return on Equity (ROE) was 2.65 % — a change of -1,632.86% (lower).

ROE

-40.58 %

YoY

-1,632.86%

Last updated:

In 2025, Immatics's return on equity (ROE) was -40.58 %, a -1,632.86% increase from the 2.65 % ROE in the previous year.

The Immatics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
75.43 EUR
Jan 1, 2020
-219.71 EUR
Jan 1, 2021
-387.88 EUR
Jan 1, 2022
17.60 EUR
Jan 1, 2023
-42.05 EUR
Jan 1, 2024
2.65 EUR
Jan 1, 2025
-40.58 EUR
The Immatics ROE history
YEARROEYoY
-40.58 %-1,632.86%
2.65 %-106.30%
-42.05 %-338.94%
17.60 %-104.54%
-387.88 %+76.54%
-219.71 %-391.28%
75.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Immatics's Return on Equity (ROE)

Immatics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Immatics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Immatics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Immatics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Immatics stock

Return on Equity (ROE) of Immatics is -40.58 % in 2025.

Return on Equity (ROE) of Immatics changed from 2.65 % to -40.58 %, representing a -1,632.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Immatics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Immatics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Immatics

All Key Metrics — Immatics